Literature DB >> 30632540

Turkish League Against Rheumatism (TLAR) Recommendations for the Pharmacological Management of Rheumatoid Arthritis: 2018 Update Under Guidance of Current Recommendations.

Şebnem Ataman1, İsmihan Sunar1, Gürkan Yilmaz1, Hatice Bodur2, Kemal Nas3, Fikriye Figen Ayhan4,4, Özgür Akgül5, Ayşen Akinci6, Zuhal Altay7, Murat Birtane8, Derya Soy Buğdayci9, Erhan Çapkin10, Remzi Çevik11, Yeşim Garip Çimen12, M Tuncay Duruöz13, Atilla Halil Elhan14, Gülcan Gürer15, Cahit Kaçar16, Ayhan Kamanli3, Ece Kaptanoğlu17, Taciser Kaya18, Hilal Kocabaş19, Ömer Kuru20, Meltem Alkan Melikoğlu21, Sumru Özel22, Aylin Rezvani23, İlhan Sezer24, Fatma Gül Yurdakul12.   

Abstract

OBJECTIVES: This study aims to report the assessment of the Turkish League Against Rheumatism (TLAR) expert panel on the compliance and adaptation of the European League Against Rheumatism (EULAR) 2016 recommendations for the management of rheumatoid arthritis (RA) in Turkey. PATIENTS AND METHODS: The EULAR 2016 recommendations for the treatment of RA were voted by 27 specialists experienced in this field with regard to participation rate for each recommendation and significance of items. Afterwards, each recommendation was brought forward for discussion and any alteration gaining ≥70% approval was accepted. Also, Turkish version of each item was rearranged. Last version of the recommendations was then revoted to determine the level of agreement. Levels of agreement of the two voting rounds were compared with Wilcoxon signed-rank test. In case of significant difference, the item with higher level of agreement was accepted. In case of no difference, the changed item was selected.
RESULTS: Four overarching principles and 12 recommendations were assessed among which three overarching principles and one recommendation were changed. The changed overarching principles emphasized the importance of physical medicine and rehabilitation specialists as well as rheumatologists for the care of RA patients in Turkey. An alteration was made in the eighth recommendation on treatment of active RA patients with unfavorable prognostic indicators after failure of three conventional disease modifying anti-rheumatic drugs. Remaining principles were accepted as the same although some alterations were suggested but could not find adequate support to reach significance.
CONCLUSION: Expert opinion of the TLAR for the treatment of RA was composed for practices in Turkish rheumatology and/or physical medicine and rehabilitation clinics.

Entities:  

Keywords:  Disease modifying anti-rheumatic drugs; Turkish League Against Rheumatism; management; rheumatoid arthritis; treatment recommendations

Year:  2018        PMID: 30632540      PMCID: PMC6328226          DOI: 10.5606/ArchRheumatol.2018.6911

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  108 in total

Review 1.  The costs of rheumatoid arthritis.

Authors:  S H Allaire; M J Prashker; R F Meenan
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 2.  The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.

Authors:  D Aletaha; J Smolen
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

3.  One-year outcomes of a randomized controlled trial of an educational-behavioural joint protection programme for people with rheumatoid arthritis.

Authors:  A Hammond; K Freeman
Journal:  Rheumatology (Oxford)       Date:  2001-09       Impact factor: 7.580

Review 4.  A clinical and economic review of disease-modifying antirheumatic drugs.

Authors:  S E Gabriel; D Coyle; L W Moreland
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 5.  Rheumatoid arthritis: direct and indirect costs.

Authors:  Anne-Christine Rat; Marie-Christophe Boissier
Journal:  Joint Bone Spine       Date:  2004-11       Impact factor: 4.929

6.  Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis.

Authors:  Fiona M McQueen; Nick Benton; David Perry; Jeff Crabbe; Elizabeth Robinson; Sue Yeoman; Lachy McLean; Neal Stewart
Journal:  Arthritis Rheum       Date:  2003-07

7.  Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients.

Authors:  D M van der Heijde; P L van Riel; M A van Leeuwen; M A van 't Hof; M H van Rijswijk; L B van de Putte
Journal:  Br J Rheumatol       Date:  1992-08

8.  Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study.

Authors:  P L C M van Riel; A J Taggart; J Sany; M Gaubitz; H W Nab; R Pedersen; B Freundlich; D MacPeek
Journal:  Ann Rheum Dis       Date:  2006-02-07       Impact factor: 19.103

Review 9.  Patient education for adults with rheumatoid arthritis.

Authors:  R P Riemsma; J R Kirwan; E Taal; J J Rasker
Journal:  Cochrane Database Syst Rev       Date:  2003

10.  Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease.

Authors:  Li Wei; Thomas M MacDonald; Brian R Walker
Journal:  Ann Intern Med       Date:  2004-11-16       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.